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Paediatric organophosphate poisoning - a rural hospital 
experience 
R Dippenaar, R J Diedericks 
Objectives. To document the presentation and course of 
organophosphate poisoning (OPP) in children and to record 
the frequency of atropine toxicity during treatment. 
Design. A retrospective observational study was conducted of 
all recorded paediatric cases of OPP admitted to a regional 
hospital over a 5-year period from 1 June 1996 to 31 May 2001. 
Setting. The study was conducted at Eben Donges Hospital, a 
regional hospital in the Boland/Overberg area of the Western 
Cape, where pesticide-intensive fruit farming remains the 
largest revenue generator. 
Subjects. The study included all children aged 12 years or less 
(as per health services classification) with confirmed OPP. 
Results. There were 23 patients. Most of the cases came from 
the. De Dooms area (35%), with poisoning by ingestion 
accounting for 61% of cases. A distinct seasonal predominance 
was found that coincided with the summer harvest. Mode of 
presentation was variable and was not related to the initial 
Eben Donges Hospital (EDH) is a regional hospital in the 
Boland/Overberg region of the Western Cape. It serves a 
diverse community whose economic stability is reliant on the 
intensive fruit-farming industry. This farming is heavily 
dependent on organophosphate (OP)-containing insecticides 
for pest control, often to the detriment of labourers' health. 
The combination of accessibility, limited legislation and lack of 
education has resulted in frequent OP exposure, including 
among children. 
Acetylcholine, the neurotransmitter at postganglionic 
parasympathetic, preganglionic sympathetic and 
parasympathetic, somatic striated skeletal and central nervous 
system (CNS) receptors, is rapidly hydrolysed by an enzyme in 
the synaptic cleft, acetylcholinesterase.1 OP compounds form 
covalent bonds with the latter resulting in an excess of 
acetylcholine, which produces hyperstimulation and the 
myriad of symptoms and signs characteristic of 
organophosphate poisoning (OPP).'-6 
Anticholinergics, in particular atropine, have been the 
cornerstone of OPP treatment for decades.' Atropine's role as a 
competitive antagonist at the muscarinic receptors in the 
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pseudocholinesterase level. Evidence of atropine toxicity 
occurred in 8 of the 18 cases treated with atropine. No 
statistically significant risk factor was found for atropine 
toxicity. The average duration of hospitalisation was 5,05 days, 
with 2 children requiring transfer to tertiary .facilities. 
Conclusions. The high number of referrals from a specific 
geographical area, combined with a 61% accidental ingestion 
rate, illustrates an area where legislation has failed to limit 
unnecessary exposure. Awareness of the seasonal 
predominance could prove pivotal to the success of future 
preventive strategies. Initial presentation and serum 
pseudocholinesterase levels did not correlate with duration of 
stay. The decision to transfer to a tertiary facility should only 
be explored once the patient has been stabilised with atropine. 
Atropine treatment is effective but carries a risk of toxicity. 
Glycopyrrolate may constitute an alternative treatment option. 
S Afr Med J 2005; 95: 678-681. 
peripheral and CNS allows rapid control of the bradycardia, 
hypotension, bronchospasm, excessive secretions and 
gastrointestinal complications of OPP, allowing for stabilisation 
of the patient.' Atropine does not reverse the effects of OPP at 
the nicotinic and all CNS receptors and patients may require 
additional support for respiratory muscle paralysis/weakness 
and convulsions, etc.' 
Atropine's biochemical structure allows it to pass through 
the blood-brain barrier, potentially reversing some of the CNS 
effects of the OPP; however it can also produce symptoms 
indistinguishable from the very condition the clinician is trying 
to treat, namely nervousness, drowsiness, mental confusion 
and agitation. These symptoms appear to be dose related and 
are a complication of treating OPP.5 
Currently there is no literature documenting the incidence of 
CNS atropine toxicity in children during OPP treatment. 
Objectives 
The study aimed to document the presentation and course of 
OPP among children treated for this condition and to record 
the frequency of CNS atropine toxicity. 
Method 
A retrospective folder review was undertaken of all paediatric 
patients (age 12 years and younger) admitted to EDH with 
confirmed OPP over a 5-year period from 1 June 1996 to 31 
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May 2001. The diagnosis of OPP was based on a combination 
of history of suspected poisoning, presenting symptoms and 
signs (Table I) and definitive confirmation using serum 
pseudocholinesterase levels. Participants' folders were 
reviewed for data on age, sex, geographical district/area of 
exposure to poison, presenting symptoms and signs, 
pseudocholinesterase level, mode of treatment, duration of 
hospital stay and documented evidence of CNS atropine 
toxicity. Atropine toxicity was defined as the persistence of 
symptoms of excessive nervousness, drowsiness, mental 
confusion, agitation or excitement after 24 hours in a child with 
dilated pupils and a clear record of repeated doses of atropine 
administration; once documented special investigations 
excluded mimicking conditions such as repoisoning with OP 
from fat stores and septicaemia. Folders with incomplete data 
and uncertain cases were excluded from the review. 
This study has the potential to improve preventive strategies 
and community awareness of the OPP problem. 
Statistical analysis 
Categorical variables were compared using the Fisher's exact 
test, and groups were compared using the Mann-Whitney U-
test. A level of significance of less than 0.05 was used 
throughout. 
Results 
During the study period 23 paediatric patients were treated for 
OPP at EDH. The demographics of these patients showed a 
male-to-female ratio of 12:11, with a median age of 4 years and 
a range of 1 - 12 years. Children from the De Dooms area in the 
Hexriver Valley accounted for 35% (N = 8) of poisonings, 
children from Worcester for 17% (N = 4), Breerivier and 
Table I. Symptoms and signs of organophosphate 
poisoning 
Muscarinic effects 
Cardiovascular system: bradycardia and hypotension 
Gastrointestinal tract: salivation, nausea and vomiting, 
diarrhoea and abdominal pain, tenesmus and faecal 
incontinence 
Respiratory system: bronchospasm, bronchorrhea 
Eyes: miosis 
Other: lacrimation, diaphoresis and urination 
Nicotinic effects 
Musculoskeletal: fasciculation, weakness, paralysis, 
cramps and respiratory paralysis 
Cardiovascular system: tachycardia and hypertension 
Central nervous system effects 
Altered level of consciousness, agitation and confusion, 
delirium, coma, seizures, ataxia, dysarthria and 
respiratory depression 
September 2005, Vol. 95, No.9 SAMJ 
Robertson for 9% (N = 2) each respectively, and the remaining 
drainage areas had incidental cases. The documented sources 
of poisoning were as follows: 61% (N = 14) accidental ingestion 
of OPs, with unwashed freshly sprayed fruit or poorly marked 
storage containers as possible sources, 22% (N = 5) skin and 
inhalation exposure as a result of recent use of OPs for pest 
control in and around homes, and 17% (N = 4) unknown or 
unconfirmed source of poisoning. There appeared to be a 
definite seasonal predominance, with cases peaking between 
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Fig. 1. Seasonal OPP incidence. 
Presenting symptoms and signs were in keeping with those 
described by other authors, with abnormal pupils (78%) and 
excessive secretions (65%) the most common features 
(Table II).? 
Table II. Summary of presenting symptoms and signs 
Pin-point pupils 
Excessive secretions 
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Skin and inhalation exposure 

























All patients admitted were treated in the same way. Initial 
conservative therapy included gastric lavage and use of 
activated charcoal (for suspected ingestion cases), declothing 
and full-body wash, and cardiovascular and respiratory 
stabilisation. A single dose of obidoxime, a cholinesterase 
reactivator, was used in 9 cases on admission. Of the 23 cases, 
20 received atropine (according to the recommended OPP 
dosage), 2 treated conservatively and 1 case received a 










Intubation was required in 4 children, of whom 2 received 
short-term (less than 24 hours) ventilation. The remaining 2 
children were transferred to a tertiary facility, 1 for intractable 
seizures not controllable with conventional anticonvulsants 
and requiring a Thiopentone infusion, and the other for 
hypoxic cerebral damage from respiratory failure and 
cardiovascular collapse. The former child survived with 
neurological impairment and the latter died 10 days after 
presentation. 
Documented evidence of CNS atropine toxicity occurred in 8 
of the 18 cases (excluding the 2 transferred patients) treated 
with atropine, equivocating to 44% of cases. No statistically 
significant difference could be found when comparing patients 
with atropine toxicity and those without toxicity (Table III). 
There was also no correlation between pseudocholinesterase 
levels and duration of stay, as shown in Fig 3. 
Discussion 
The liberal use of pesticides in the agriculturally rich region of 
the Western Cape has contributed significantly to the ever-
increasing number of reported poisonings in this region. 
Pesticide poisoning in children under 14 years of age has a 
reported average incidence of 0.367/100 000. OPP accounts for 
49.9% of all poisonings." OPP is a notifiable disease in South 
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Fig. 3. Scatter plot of pseudocholinesterase level v. duration of stay. 
Africa and it can be assumed that the reported numbers are a 
gross underestimation of the real problem.' Our study region is 
well represented in the above statistic. 
The seasonal predominance between October and January is 
an overriding feature of these poisonings. The fact that 
incidence coincides with peak spraying activities (a trend also 
noted by other authors) could prove pivotal to the success of 
future preventive strategies.10 OPP indicates a problem of 
increased exposure to and circulation of agricultural pesticides. 
More stringent enforcement of current legislation is required, 
along with a need for education. Education of both employees 
and employers cannot be overemphasised, as this remains 
pivotal in reducing exposure to these hazardous chemicals, 
especially among children. Legislation forcing farms to erect 
clear signage warning children and adults to keep away from 
recently sprayed areas may be an effective solution. School-
based programmes (as attempted by the Department of Health 
a few years ago) and child-to-child programmes should be 
introduced. The high number of referrals from the De Dooms 
area (35%) in combination with 61% of poisonings by 
accidental ingestion indicates a high-risk area that would 
benefit from a structured education programme. Legislation, 
particularly in the De Dooms area, should be more strictly 
enforced, with seasonal air monitoring, more stringent control 
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interpreted as allowing children over 14 to consent 
independently to 'therapeutic' research? 
Researchers will now face new legal requirements that may 
affect recruitment and informed consent processes. Although 
the National Health Act' will not operate retrospectively, once 
it is implemented researchers may have to change current 
practices if they are not in line with the new provisions. 
Aspects of the emerging ethical-legal framework are 
ambiguous and inconsistent 
Key problems raised at the forum included: 
1. The National Health Act' retains the contested distinction 
between 'therapeutic' and 'non-therapeutic' research in its 
provisions relating to research with children, despite the fact 
that most research contains interventions not intended to 
confer direct benefit to participants. It does not define either 
term. 
2. It is not clear how the different phases of HIV vaccine trials 
would be classified in terms of the above distinction. 
3. If HIV vaccine trials are classified as 'non-therapeutic' 
research (as early trials might be) the risk standard of 'not 
significant' risk must be met. There was some debate as to 
whether the above term introduced a more relaxed standard 
of risk for research involving children or alternatively 
whether it was substantively identical to current risk 
standards (routine tests or daily life). There was some debate 
as to whether the risks of HIV vaccine research (such as 
vaccine administration, risk assessments) could meet this 
standard set by the National Health Act.' 
4. There are many inconsistencies between the National Health 
Act' and other critical pieces of legislation such as the 
Children's Bill! For example, the National Health Act' 
requires dual consent for research from parents or legal 
guardians and where children are capable of understanding, 
children themselves.8 This differs from the approach taken in 
the Children's Bill' which provides for independent consent 
by a child of a specified age and capacity (albeit in the case 
of medical treatment and operations and not research), 
which creates a wider category of persons who are able to 
act on a child's behalf,' and which requires that the views of 
a child be given due consideration bearing in mind the age, 
maturity and stage of development of the child.10 
5. The National Health Act' requires 'therapeutic' research to be 
conducted only if it is in the 'best interests' of the child.n No 
guidance is provided in the Act on how one establishes what 
these 'best interests' are. 
6. Both the National Health Act' and the Children's Bill' 
provide that in the event of an inconsistency their provisions 
will prevail. 
7. Four ethical guidelines relevant to HIV vaccine research5•6"'·13 
offer some contradictory guidance regarding child 
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participation on the following points: (i) the approach taken 
towards the analysis of risk and classification of research; (ii) 
the name given to risk levels allowed for child research, and 
the substance of the risk level allowed for child research; (iii) 
who has the authority to consent for child participation; and 
(iv) what risk parents or guardians are permitted to consent 
to on behalf of children when there is no direct benefit to the 
child and when there is a direct benefit 
It is the MRC's General Principles' that are most disjunctive 
with the other three increasingly well-harmonised guide-
lines.5'12'13 As a result of these ambiguities and inconsistencies 
REC members reviewing trials and researchers planning trials 
may struggle to screen out 'unethical' or unlawful research 
practices involving child participants, 
In some instances, the ethical-legal framework does 
not protect child welfare or promote critical research 
as effectively as possible 
The following issues were discussed: 
1. Section 71 of the National Health Act' purports to deal with 
the rights of children participating in research; however, it 
focuses on informed consent without considering other 
protections such as a child's right to privacy. As a result, 
there are many instances in which child research participants 
do not have explicit legal protection in South African law. 
2. The National Health Act' creates additional procedural 
requirements that may burden investigators and RECs, e.g. 
when 'non-therapeutic' research is conducted on children 
then 'authorisation from the Minister' must be obtained.14 
Furthermore, the Minister is obliged to follow guidelines set 
down in the Act, in determining whether authorisation for 
non-therapeutic research should be approved. Concerns 
were raised regarding: (i) how this provision would operate 
in practice; (ii) whether it would delay research classified as 
'non-therapeutic'; and (iii) how the Minister would interpret 
poorly drafted requirements such as that research may only 
be authorised if the parent or minor's reasons for consenting 
to the research are not contrary to public policy. 
3. Certain ethical guidelines are restrictive in their approach, 
e.g. the Medical Research Council's General Principles6 
permit parents to enroll their children in 'non-therapeutic' 
research only if it is 'observation' research, and research with 
risks not exceeding everyday life. This approach may 
prevent the enrolment of healthy children in intervention 
research such as clinical trials of prevention products. 
Recommendations 
A number of recommendations were made at the forum to 
promote a more coherent framework that facilitates critical 
research with child participants, including adolescents, while 
promoting their rights and welfare. These included the 
following. 
r----------------------------------------------~------------- - -
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Capacity should be built for stakeholders to better 
understand the strengths, weaknesses and 
implications of the framework, and mechanisms 
should be developed to allow them to impact on the 
framework 
It was recognised that in many instances stakeholders felt 
unable to participate in the ethical-legal framework or impact 
on its development because of a lack of capacity. Accordingly it 
was recommended that: (i) the capacity of community 
representatives, RECs and investigators should be developed 
to enable them to understand the relevant laws and guidelines, 
and their interpretation in relation to HIV vaccine research; (ii) 
an accurate understanding of the perspectives and concerns of 
participating communities should be established through 
sensitive research and consultation; and (iii) mechanisms 
should be developed whereby stakeholders, such as RECs, can 
liaise on the interpretation of laws or guidelines in order to 
aspire towards consistent protocol review. 
Law reform and the revision of ethical guidelines is 
required 
The following was recommended: (i) input should be made to 
the regulations that will accompany the National Health Act in 
order to resolve certain inconsistencies and ambiguities in the 
Act;3 (ii) proposals to include the rights of child research 
participants in the Children's Bill' should be supported; and 
(iii) revisions should be made to ethical guidelines5•6 that ensure 
their harmonisation and ability to protect child participants 
while accommodating sound research. 
Appropriate tools should be developed 
It was recommended that tools and tests should be developed 
to facilitate the appropriate implementation of a number of the 
new requirements set out in the National Health Act including: 
(i) children's 'understanding' of research participation; (ii) 
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determining 'public policy'; and (iii) determining the 'best 
interests of the child'. 
In conclusion, a transitory and inconsistent framework 
complexities research involving adolescent or child 
participants. Considerable training, law reform, guideline 
amendment and tool development are required to better 
protect these participants and to facilitate critical research to 
promote their health. 
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